Lipella Pharmaceuticals (LIPO) Competitors $0.60 0.00 (-0.03%) As of 12:08 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. INAB, SNSE, SONN, CARM, NLSP, HOOK, PHIO, CLDI, TAOX, and BFRIShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include IN8bio (INAB), Sensei Biotherapeutics (SNSE), Sonnet BioTherapeutics (SONN), Carisma Therapeutics (CARM), NLS Pharmaceutics (NLSP), HOOKIPA Pharma (HOOK), Phio Pharmaceuticals (PHIO), Calidi Biotherapeutics (CLDI), Synaptogenix (TAOX), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Its Competitors IN8bio Sensei Biotherapeutics Sonnet BioTherapeutics Carisma Therapeutics NLS Pharmaceutics HOOKIPA Pharma Phio Pharmaceuticals Calidi Biotherapeutics Synaptogenix Biofrontera Lipella Pharmaceuticals (NASDAQ:LIPO) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Does the media favor LIPO or INAB? In the previous week, IN8bio had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 2 mentions for IN8bio and 0 mentions for Lipella Pharmaceuticals. IN8bio's average media sentiment score of 0.44 beat Lipella Pharmaceuticals' score of 0.00 indicating that IN8bio is being referred to more favorably in the news media. Company Overall Sentiment Lipella Pharmaceuticals Neutral IN8bio Neutral Do institutionals and insiders have more ownership in LIPO or INAB? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 15.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is LIPO or INAB more profitable? IN8bio has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. IN8bio's return on equity of -184.97% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% IN8bio N/A -184.97%-126.75% Do analysts rate LIPO or INAB? IN8bio has a consensus price target of $180.00, suggesting a potential upside of 7,935.71%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Lipella Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, LIPO or INAB? Lipella Pharmaceuticals has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K4.98-$5.02M-$3.43-0.17IN8bioN/AN/A-$30.44M-$9.11-0.25 Which has more volatility & risk, LIPO or INAB? Lipella Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. SummaryIN8bio beats Lipella Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.67M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-0.1520.4030.4525.16Price / Sales4.98238.54392.5887.64Price / CashN/A42.3737.0358.50Price / Book0.387.918.956.21Net Income-$5.02M-$54.72M$3.26B$265.38M7 Day Performance-5.16%1.63%1.06%-1.13%1 Month Performance-25.31%5.86%4.31%-0.71%1 Year Performance-83.10%8.70%28.40%18.89% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella PharmaceuticalsN/A$0.600.0%N/A-82.5%$2.67M$536.36K-0.154INABIN8bio3.8593 of 5 stars$2.28-4.6%$180.00+7,794.7%-86.0%$10.28MN/A-0.2520Short Interest ↓SNSESensei Biotherapeutics4.2727 of 5 stars$8.11-2.0%$55.00+578.6%-37.4%$10.21MN/A-0.3840SONNSonnet BioTherapeutics2.7933 of 5 stars$3.20-4.5%$20.00+525.0%-44.1%$10.14M$20K0.0010Gap UpCARMCarisma Therapeutics3.0677 of 5 stars$0.24-13.6%$1.93+698.8%-79.0%$10.07M$19.63M-0.1520News CoveragePositive NewsShort Interest ↓NLSPNLS PharmaceuticsN/A$2.79+8.1%N/A+1,388.9%$10.03MN/A0.006Short Interest ↓HOOKHOOKIPA Pharma3.325 of 5 stars$0.82-3.8%$4.50+451.8%-83.6%$9.94M$9.35M-0.14160Positive NewsPHIOPhio Pharmaceuticals2.6241 of 5 stars$2.04-5.3%$14.00+588.0%-34.0%$9.86MN/A-0.6310Earnings ReportCLDICalidi Biotherapeutics0.7987 of 5 stars$3.09-24.7%N/A-90.7%$9.85MN/A0.0038News CoverageTAOXSynaptogenixN/A$6.90-17.3%N/AN/A$9.59MN/A-0.344Earnings ReportGap DownBFRIBiofrontera2.8249 of 5 stars$0.94+0.8%$2.75+193.5%-30.7%$9.51M$37.32M-0.4270Gap Down Related Companies and Tools Related Companies INAB Competitors SNSE Competitors SONN Competitors CARM Competitors NLSP Competitors HOOK Competitors PHIO Competitors CLDI Competitors TAOX Competitors BFRI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access